INTRODUCTION
Anaphylaxis is a serious, rapid-onset allergic reaction that in rare cases causes death [1] . Recent evidence demonstrates that pediatric emergency department (ED) visits for children with anaphylaxis increased from 5.7 to 11.7 per 10 000 visits from 2009 to 2013, and that the overall burden of childhood allergic disease is increasing [2, 3] . This highlights the need for providers and the lay public to have a heightened awareness for a diagnosis that has been underrecognized and undertreated. In 2010, the National Institute of Allergy, Immunology, and Infectious Diseases (NIAID) published its comprehensive guideline for managing food allergy [4] . The presence of any one of the following indicates that anaphylaxis is likely:
(1) Acute hives or angioedema along with either respiratory symptoms or hypotension (2) Rapid occurrence of at least two of these signs after an exposure to a likely antigen: (a) Hives or angioedema (b) Respiratory symptoms (c) Hypotension (d) Gastrointestinal symptoms (3) Hypotension after exposure to a known allergen The NIAID definition serves to alert the provider to the various presentations that anaphylaxis may have, and directs the provider to keep a high level of suspicion for anaphylaxis and the need for timely treatment.
We will highlight recent advances in the general care of patients with anaphylaxis. We will review updates on diagnostic testing, treatment with epinephrine and adjuvant medications, stronger evidence on the true risk of biphasic reactions, and the nuanced approach to the length of ED observation prior to discharge. The review of fluid resuscitation and airway support for anaphylactic shock are beyond the scope of this article.
DIAGNOSTIC TESTING
Histamine, platelet-activating factor (PAF), and tryptase have shown promise for diagnosing anaphylaxis. Although histamine likely does not have the ability to discriminate between anaphylactic and nonanaphylactic allergic reactions, tryptase may be useful if a patient-specific basal tryptase level is available [5, 6] . Most promisingly, PAF was elevated in 20% of patients with cutaneous-only allergic reactions, in 67% of anaphylactic reactions without hypotension or serious respiratory involvement, and in 100% of patients with those severe anaphylactic signs [5] . This suggests a role for PAF in unclear or severe cases. PAF is likely involved in the pathogenesis of anaphylaxis [7] . Future clinical research could focus on the prognostic features of PAF. We do not commonly obtain diagnostic testing in patients with allergic symptoms to establish a diagnosis of anaphylaxis.
EPINEPHRINE
Intramuscular (IM) epinephrine delivered to the anterolateral thigh is the mainstay of therapy for anaphylaxis. Its vasoconstrictive a-1 adrenergic effects treat shock and decrease airway edema; its mast cell stabilization activity decreases histamine release; and its b-2 adrenergic effects cause bronchodilation [8 & ]. Epinephrine should always be used as the first-line treatment for anaphylaxis, as supported by epidemiological data, animal studies, data on mechanism of action, and consensus opinions based on years of clinical experience [9, 10] . Delay in epinephrine delivery is associated with a higher risk of fatal anaphylaxis [9, 11] . In a large series of fatal cases, only 21 of 92 patients received epinephrine before cardiac arrest [10] .
The dose of epinephrine for anaphylaxis is 0.01 mg/kg, given IM using the 1 : 1000 concentration [4] . It can be drawn up via syringe or given by epinephrine autoinjector (EAI). Intravenous epinephrine is avoided because of the risk of dysrhythmia, except when a continuous infusion is needed for refractory, severe cardiorespiratory disease.
EAIs are available in adult, 0.3 mg devices for patients weighing at least 25 kg, or junior 0.15 mg devices for children under 25 kg. Although some have expressed concern for infants weighing less than 10 kg receiving the junior EAI, we and others [12] believe the benefits outweigh the risks in otherwise healthy infants outside the hospital setting. In the hospital, infants under 10 kg should receive weight-based epinephrine 1 : 1000 IM to best approach 0.01 mg/kg. Potential common adverse effects include jitteriness, pallor, and anxiety after administration of doses higher than 0.01 mg/kg, and the concern for injecting the EAI into bone [13] . The discharge process should always include careful teaching on EAI use to avoid misuse [14] . Lack of improvement or worsening symptoms should prompt repeat epinephrine, which can be administered IM up to every 5-15 min, or as an intravenous infusion [15 & ].
ADJUVANT MEDICATIONS
The 2010 NIAID guidelines acknowledged a lack of evidence to support glucocorticoids and antihistamines as routine medications used to treat anaphylaxis [4] . Nevertheless, this national consensus guideline recommends these medications in the ED setting. Glucocorticoids are well established for the treatment of asthma and airway edema [16, 17] . A recent study showed a reduced risk of prolonged hospitalization among children hospitalized for anaphylaxis who received glucocorticoids [18] . However, glucocorticoids did not significantly reduce the risk of relapse in adults with anaphylaxis [19] . In the absence of a clinical trial to guide decision making, we believe steroids should be given in the ED as adjuvant treatment, especially to patients with asthma or airway edema. Evidence to guide outpatient use of glucocorticoids is sparse, but 48-72 h of continuing treatment based on the time window of biphasic reactions is typical. Although histamine-1 blockers such as diphenhydramine can reduce urticaria, they do not impact the underlying pathophysiology of anaphylaxis, and therefore have no role as a substitute for epinephrine. Controlled trials of histamine-1 blockers are unlikely in anaphylaxis. We believe it is reasonable to give antihistamines in the ED as adjuvant treatment to improve comfort, especially to patients with urticaria or angioedema. The role of histamine-2 blockers such as ranitidine is also unclear but has efficacy for adults with urticaria [20] . No studies have specifically assessed their efficacy for treating anaphylaxis [21] . Therefore, we believe that routine use is unnecessary.
BIPHASIC REACTIONS
A six-fold increase in anaphylaxis hospitalizations in the face of stable mortality rates (0.047 cases per 100 000 population) was observed over the past 20 years [22] . This may be because of the rising concern that many patients with anaphylaxis are at risk for biphasic reactions, a late recrudescence of anaphylaxis. However, the incidence of clinically important biphasic reactions is low. In children, past evidence suggested a rate of biphasic reactions as high as 20%, but recent data suggest it is much lower [23, 24] . Among adults, the strongest recent evidence shows a 1-4% rate of biphasic reactions, with most occurring within 8 hours [25, 26, 27 & ].
MONITORING AND DISPOSITION
The most recent ED practice parameter for anaphylaxis recommends that providers 'strongly consider observing patients who have experienced anaphylaxis for at least 4-8 h and observe patients with a history of risk factors for severe anaphylaxis for a longer period' [15 & ]. Risk factors include asthma, previous biphasic or protracted anaphylaxis, repeat doses of epinephrine, wheezing, hypotension, or pharyngeal edema [25] .
Given that signs and symptoms of anaphylaxis can return as epinephrine is metabolized, it is prudent to observe all patients for at least 3-4 h in the ED after administration of epinephrine. We believe institutions should adopt clinical practice guidelines to reduce observation periods in low-risk patients, and we propose one candidate guideline (Table 1) .
PREVENTION OF ANAPHYLAXIS
The incidence of anaphylaxis has increased over the past 15 years [2, 3] . This is likely related to an increase in food allergy; peanut allergies have tripled in the past 10-15 years and now affect one in 50 children [28] . In the 2015 Learning Early About Peanut Allergy (LEAP) trial, high-risk infants between 4 and 11 months of age who were randomized to peanut avoidance had a significantly higher prevalence (13.7 versus 1.9%) of peanut allergy at 5 years of age compared to those randomized to peanut consumption [28,29 && ]. This provides strong evidence in favor of early introduction of peanut to atopic children and raises the possibility that similar strategies could be effective for other foods or for the general population. 
CONCLUSION
The prevalence of allergic disease is increasing and warrants providers being current on the management of anaphylaxis to prevent morbidity and mortality. Epinephrine is the first-line therapy to treat anaphylaxis, and EAIs should be utilized by caretakers and field providers. Adjuvant therapies may be helpful, and we routinely use glucocorticoids and histamine-1 blockers. We recommend monitoring patients for no longer than 3-4 h after epinephrine in low-risk patients who have rapid symptom resolution. Future research should focus on the effectiveness of adjuvant medications, clarifying which subpopulations of patients are at risk for biphasic reaction, and identifying foods other than peanut for which early sensitization would prevent allergy. Atopic infants randomized at age 4-11 months to peanut avoidance had a higher (13.7%) peanut allergy prevalence at age 60 months than those randomized to consume peanut (1.9%). This indicates that pediatricians should recommend against peanut avoidance in atopic infants.
